Buscar
01/05/2025
Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice
Olveira, A, Crespo, J, Samaniego, LI, Gallego-Durán, R, Panero, JLC, Aller, R, Soria, A, Gómez-Camarero, J, Martin-Mateos, R, Benlloch, S, Pericàs, JM, Morillas, RM, Bernal, V, Diago, M, Turnes, J, Poca, M, Lo Iacono, O, Escudero-García, D, Andrade, RJ, Rosales-Zábal, JM, Jorquera, F, Fernández-Rodríguez, C, Guerra, MH, Romero-Gómez, M, Herrojo, JA. Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study
Guerrero, A, Verdyguer, MR, Martínez, SM, Campos, M, Sogbe, M, Fajes, JLH, Pascual, S, Cuyas, B, Minguez, B, Lamas-Alvarez, S, Fortea, J, Lopez-Fando, MPV, Lozano, MD, Gómez-Rubio, M, Perelló, C, Gutiérrez, ML, Romero-Gutiérrez, M, Mancebo, A, Planas, JMM, Téllez, L, Panero, JLC, De la Poza, G, Piqueras, B, Puente, A, Varela, M, Genesca, J, Alvarado-Tapias, E, D'Avola, D, Matilla, A, Sangro, B, Reig, M, Lledó, JL, Albillos, A. Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT). A long-term follow-up study
Alabau, BB, Plessier, A, Sanchez, FB, Payancé, A, Ballester, TG, Elkrief, L, Sánchez-Lorenzo, A, Larrue, H, Donate, J, Vidal-González, J, Praktiknjo, M, González-Alayón, C, Tripathi, D, Fortea, J, Gioia, S, alvarez-Navascués, C, Raevens, S, Herrera, EL, Protopapas, A, Nery, FGC, Artaza, T, La Mura, V, Baiges, A, Ollivier-Hourmand, I, Darnell, A, Zekrini, K, Belmonte, E, García-Criado, MA, Turon, F, Hernández-Gea, V, Verhelst, X, Riggio, O, Puente, A, Simon-Talero, M, Téllez, L, Bureau, C, Alvarado-Tapias, E, Ballester, MP, Rautou, PE, García-Pagán, JC. Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT). A long-term follow-up study. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Metabolic dysfunction-and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort
Younossi, Z, de Avila, L, Petta, S, Nakajima, A, Crespo, J, Kim, SU, Castera, L, Zheng, MH, Tsochatzis, E, Trivikrama, SK, Shalimar, S, Alswat, KA, Yilmaz, Y, Yu, ML, Francque, S, Chan, WK, Fernández, MIC, Treeprasertsuk, S, Duseja, AK, Gadano, A, Oliveira, CP, Arab, JP, Papatheodoridis, G, Diaz, LA, Sebastiani, G, D'Ambrosio, R, Valsan, A, Khalid, A, Holleboom, AG, El-Kassas, M, Pugliese, N, Singal, AK, Pearlman, B, Choudhary, NS, Cordie, A, Gunn, N, Caussy, C, Mauricio, D, Kawaguchi, T, Russo, FP, Venu, A, Hagström, H, Alkhouri, N, Ananchuensook, P, Mohan, L, Fan, JA, Roberts, S, Wong, VWS, Dunn, W, Ekstedt, M, Goh, GBB, Pessoa, M, Lampertico, P, Pennisi, G, Shang, Y, Liu, WY, Lee, HW, Kobayashi, T, Kakizaki, S, Iruzubieta, P, Nadeem, R, Cinque, F, Neonaki, A, Zoncapè, M, Yang, RX, Song, SJ, Dunn, N, Gadi, Z, Yeh, ML, Teh, KKJ, Mahadeva, S, Fabian, LG, Almohsen, A, Leite, N, Vessby, J, Xie, CC, Friend, E, Poca, M, Segrestin, B, Arrese, M, Lam, B, Racila, A, Alqahtani, S, Stepanova, M. Metabolic dysfunction-and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Phase angle as a predictive factor for mortality in hospitalized patients with cirrhosis
Javier, FO, Sánchez, J, Roman, E, Miquel, M, Kaur, N, Ferrusquía-Acosta, J, Poca, M, Solé, C, Cuyàs, B, Casas, M, Alvarado-Tapias, E, Monllor-Nunell, T, Sheila, A, Andreu, F, Brujats, A, Vergara, M, Escorsell, A, Soriano, G. Phase angle as a predictive factor for mortality in hospitalized patients with cirrhosis. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Dynamics and prognostic implications of splanchnic volumetry in patients withportosinusoidal vascular liver disorder
Ferrusqu a-Acosta, J, Gil-Bello, D, Lampichler, K, Vidal, M, Fuertes, D, Simonis, L, Wu, CJ, Shen, Y, Luo, XF, G mez, FT, Parada-Bl zquez, MJ, Gir ldez-Gallego, A, S nchez-Lorenzo, A, Selva-Tal n, D, Alvarado-Tapias, E, Saltini, D, Squecco, D, Schepis, F, Giudicelli, H, Wagner, M, Thabut, D, Garc a-Calonge, M, Uceda-Andr s, E, Alvarez-Navascu s, C, Koc, O, Miclea, R, Maderuelo, E, Herrera, EL, Casas, M, Miquel, M, Vergara, M, Balcar, L, S nchez, J, Sol , C, Scheiner, B. Dynamics and prognostic implications of splanchnic volumetry in patients withportosinusoidal vascular liver disorder. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Anemia following portal hypertension-related bleeding in liver cirrhosis: incidence and impact on prognosis
Ojeda, A, Magaz, M, Agulleiro, I, Pascual, I, Jimenez-Esquivel, N, Pèlach, A, Cháfer, IT, García-García, S, Maderuelo, E, Puente, A, Cobreros, M, Gonzalez, JV, Amador, A, Alvarado-Tapias, E, Gonzílez-Alayón, C, Téllez, L, Manzano, F, Bernal, V, Lomas, R, Ferrusquía-Acosta, J, Perez, V, Shalaby, S, Baiges, A, Turon, F, Hernández-Gea, V, Romero-Gutiérrez, M, Vives-Moreno, J, Albillos, A, Morant, A, Alonso, JC, Simón-Talero, M, Fortea, J, Herrera, EL, Aguilera, V, Masnou, H, Giráldez-Gallego, A, García-Pagán, JC. Anemia following portal hypertension-related bleeding in liver cirrhosis: incidence and impact on prognosis. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality
Younossi, Z, de Avila, L, Petta, S, Hagström, H, Kim, SU, Nakajima, A, Crespo, J, Castera, L, Alkhouri, N, Zheng, MH, Treeprasertsuk, S, Ananchuensook, P, Shalimar, S, Tsochatzis, E, Trivikrama, SK, Mohan, L, Fan, JA, Roberts, S, Alswat, KA, Wong, VWS, Yilmaz, Y, Dunn, W, Francque, S, Cordie, A, Yu, ML, Ekstedt, M, Goh, GBB, Oliveira, CP, Pessoa, M, Chan, WK, Fernández, MIC, Duseja, AK, Arab, JP, Papatheodoridis, G, Sebastiani, G, Villela-Nogueira, C, D'Ambrosio, R, Lampertico, P, Khalid, A, Holleboom, AG, Valsan, A, El-Kassas, M, Pennisi, G, Shang, Y, Liu, WY, Lee, HW, Kobayashi, T, Kakizaki, S, Caussy, C, Pearlman, B, Iruzubieta, P, Nadeem, R, Cinque, F, Neonaki, A, Zoncapè, M, Yang, RX, Song, SJ, Dunn, N, Gadi, Z, Yeh, ML, Teh, KKJ, Mahadeva, S, Fabian, LG, Almohsen, A, Leite, N, Pugliese, N, Vessby, J, Xie, CC, Choudhary, NS, Friend, E, Poca, M, Kawaguchi, T, Russo, FP, Gadano, A, Singal, AK, Diaz, LA, Ségrestin, B, Gunn, N, Mauricio, D, Arrese, M, Lam, B, Racila, A, Alqahtani, S, Stepanova, M. A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).